

Amendments to the Claims

Claims 1-85 (Canceled).

Claim 86 (New). A glycoengineered, recombinant antibody comprising an Fc region containing N-linked oligosaccharides, wherein said antibody has been engineered to have an altered pattern of glycosylation in the Fc region and wherein said antibody has increased Fc-mediated cellular cytotoxicity as a result of said altered glycosylation.

Claim 87 (New). A glycoengineered, recombinant antibody comprising an Fc region containing N-linked oligosaccharides, wherein said antibody has been engineered to have an altered pattern of glycosylation in the Fc region and wherein said antibody has increased Fc receptor binding affinity as a result of said altered glycosylation.

Claim 88 (New). A glycoengineered, recombinant antibody according to claim 86 or claim 87, wherein said antibody is a chimeric antibody.

Claim 89 (New). A glycoengineered, recombinant antibody according to claim 86 or claim 87, wherein said antibody is a humanized antibody.

Claim 90 (New). A glycoengineered, recombinant antibody according to claim 86 or claim 87, wherein said antibody is an antibody fragment that contains the Fc region.

Claim 91 (New). A glycoengineered, recombinant antibody according to claim 86 or claim 87, wherein said antibody is a fusion protein that includes a Fc region of an immunoglobulin.

Claim 92 (New). A glycoengineered, recombinant antibody according to claim 86 or claim 87, wherein said altered pattern of glycosylation is an increase in the proportion of GlcNAc residues compared to the nonglycoengineered recombinant antibody.

Claim 93 (New). A glycoengineered, recombinant antibody according to claim 86 or claim 87, wherein said altered pattern of glycosylation is a decrease in the proportion of fucose residues compared to the nonglycoengineered recombinant antibody.

Claim 94 (New). A glycoengineered, recombinant antibody according to claim 86 or claim 87, wherein said altered pattern of glycosylation is an increase in the proportion of GlcNAc residues relative to the proportion of fucose residues compared to the nonglycoengineered recombinant antibody.

Claim 95 (New). A glycoengineered recombinant antibody according to claim 92, wherein said oligosaccharides are bisected.

Claim 96 (New). A glycoengineered, recombinant antibody according to claim 92, wherein said oligosaccharides are bisected, complex.

Claim 97 (New). A glycoengineered, recombinant antibody according to claim 92, wherein said oligosaccharides are bisected, hybrid.

Claim 98 (New). A glycoengineered, recombinant antibody according to claim 86 or claim 87, wherein said antibody is isolated from an engineered host cell selected from the group consisting of an engineered CHO cell, an engineered BHK cell, an engineered NS0 cell, an engineered SP2/0 cell, an engineered yeast cell, and an engineered plant cell.

Claim 99 (New). A glycoengineered, recombinant antibody according to claim 98, wherein said antibody is isolated from an engineered CHO cell.

Claim 100 (New). A glycoengineered, recombinant antibody according to claim 86 or claim 87, wherein said antibody is a therapeutic antibody.

Claim 101 (New). A glycoengineered, recombinant antibody according to claim 100, wherein said antibody selectively binds to a cancer antigen.

Claim 102 (New). A glycoengineered, recombinant antibody according to claim 100, wherein said antibody is a monoclonal antibody.

Claim 103 (New). A glycoengineered recombinant antibody according to claim 100, wherein said antibody is a selected from the group consisting of: an anti-CD20 antibody, an anti-human neuroblastoma antibody, an anti-human renal cell carcinoma antibody, an anti-HER2 antibody, an anti-human colon, lung, and breast carcinoma antibody, an anti-human 17-1A antigen antibody, a humanized anti-human

colorectal tumor antibody, an anti-human melanoma antibody, and an anti-human squamous-cell carcinoma antibody.

Claim 104 (New). A glycoengineered, recombinant antibody according to claim 86 or claim 87, wherein said antibody is IgG.

Claim 105 (New). A glycoengineered, recombinant antibody according to claim 86 or claim 87, wherein the majority of the N-linked oligosaccharides are bisected.

Claim 106 (New). A glycoengineered, recombinant antibody according to claim 86 or claim 87, wherein the majority of the N-linked oligosaccharides are nonfucosylated.

Claim 107 (New). A glycoengineered, recombinant antibody according to claim 86 or claim 87, wherein the majority of the N-linked oligosaccharides are bisected, nonfucosylated.

Claim 108 (New). A glycoengineered, recombinant antibody produced by a process comprising:

- (a) providing a glycoengineered host cell comprising at least one nucleic acid encoding a recombinant antibody and at least one nucleic acid encoding a glycosyltransferase;
- (b) culturing said host cell under conditions which permit expression of said recombinant antibody having an altered pattern of glycosylation in the Fc region of said antibody; and
- (c) isolating said recombinant antibody;

wherein said recombinant antibody has increased Fc-mediated cellular cytotoxicity as a result of said altered glycosylation.